Scientists report a noninvasive nanomedicine that eliminated deadly brain tumours in mice. The work addresses a key problem in glioblastoma treatment: medicines rarely reach tumours at effective levels. The findings appear in PNAS.
The approach uses spherical nucleic acids, structures made by arranging short DNA strands densely around a nanoparticle core. Chad A. Mirkin, who invented spherical nucleic acids, worked with a team led by Alexander H. Stegh at Washington University in St. Louis Medicine and Siteman Cancer Center. Akanksha Mahajan is first author on the study.
The researchers made particles with gold cores and DNA designed to activate STING (stimulator of interferon genes). They delivered droplets into the nasal passages and used a near-infrared molecular tag to track the nanomedicine along the main nerve that connects facial muscles to the brain. The therapy concentrated in immune cells near and in the tumour and triggered helpful responses in lymph nodes. Given with drugs that boost T lymphocytes, one or two doses eradicated tumours and produced long-term immunity, outperforming STING drugs that need direct tumour injection.
Difficult words
- treatment — A way to help or cure illness.treatments
- glioblastoma — A serious type of brain cancer.
- noninvasive — Not needing surgery or cuts.
- immune — Related to the body's defense against sickness.immune-resistant
- activate — To start or make something work.
- pathway — A route or method used by cells.
- enhancing — Making something better or stronger.
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- What do you think about using nasal drops for medication?
- How could this treatment change cancer care in the future?
- What other diseases might benefit from similar treatments?
Related articles
Needle-free spray delivers last-resort antibiotics
Researchers developed a needle-free spray-mist device to push last-resort antibiotics through the skin into infected tissue. The method aims to treat drug-resistant infections while reducing organ damage linked to intravenous delivery.
Lower chemotherapy dose helps people 80+ with lymphoma
A study found that people aged 80 and older with a common lymphoma often do better with a lower chemotherapy dose. Researchers used data from community cancer clinics and say the smaller dose kept effectiveness while reducing side effects.